AZ/Lilly Alzheimer’s drug given fast-track status
AstraZeneca and Eli Lilly’s experimental Alzheimer’s disease drug AZD3293 has been issued a Fast Track designation in the US potentially speeding up the drug regulatory pathway.
Read More
Tag: AZD3293
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
